## An Expedient Synthesis of Pyrrolo[3,2,1-*ij*]quinoline-1,2-diones via Intramolecular Friedel–Crafts Cyclization Protocol


Hye Ran Moon, Su Yeon Kim, Jin Woo Lim, and Jae Nyoung Kim\*

Department of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Korea. \*E-mail: kimjn@chonnam.ac.kr Received April 15, 2015, Accepted July 17, 2015, Published online September 28, 2015

**Keywords:** Pyrrolo[3,2,1-*ij*]quinoline-1,2-diones, Intramolecular Friedel–Crafts reaction, Morita–Baylis–Hillman bromides, Isatins

The pyrrolo[3,2,1-*ij*]quinolines and their reduced or oxidized derivatives have received much attention due to their diverse biological functions including analgesic, anti-inflammatory, anti-epileptic, and anticancer activities.<sup>1–3</sup> In spite of the broad applicability and rising interest from synthetic chemists, the reported methods for the preparation of pyrrolo[3,2,1-*ij*] quinolines are rather scarce.<sup>1–3</sup> Recently, Skropeta and co-workers reported the synthesis of pyrrolo[3,2,1-*ij*]quinoline-1,2-diones via a palladium-catalyzed C<sub>7</sub>-*N* annulation of 7-bromo-*N*-substituted isatins (Scheme 1, Eq. 1).<sup>2a</sup> However, the yields were very low (8–39%). France *et al.* reported the synthesis of pyrrolo[3,2,1-*ij*]quinolin-4-ones via an In(OTf)<sub>3</sub>-mediated intramolecular Friedel–Crafts (IMFC) approach (Scheme 1, Eq. 2).<sup>2b</sup>

During our recent interest in IMFC reactions<sup>4</sup> and the chemical transformations of isatin derivatives,<sup>5</sup> we reasoned out that pyrrolo[3,2,1-*ij*]quinoline-1,2-diones could be prepared via an IMFC approach as shown in Scheme 1 (Eq. (3)). We expected that the IMFC reaction would proceed under suitable reaction condition although the benzene ring of isatin moiety is deactivated because of the presence of an electron-




Scheme 1. Synthesis of pyrrolo[3,2,1-ij]quinoline.

withdrawing carbonyl group. To the best of our knowledge, there is no report on inter- and intramolecular Friedel–Crafts alkylation of isatins.

The starting materials **3a–f** were prepared from Morita– Baylis–Hillman (MBH) bromides **1** and isatins **2** in the presence of K<sub>2</sub>CO<sub>3</sub> in CH<sub>3</sub>CN at room temperature, as shown in Scheme 2.<sup>6,7</sup> The yields of **3a–f** were good (83–89%).

Initially, we examined the IMFC reaction of 3a in polyphosphoric acid (PPA)<sup>8</sup> at 90 °C. To our delight, pyrrolo[3,2,1-*ij*] quinoline-1,2-dione 4a was obtained in good yield (68%) along with Friedel-Crafts acylation product 5a in low yield (15%). Compound 4a was formed diastereoselectively, and the relative stereochemistry between the substituents at 5and 6-positions would be a trans relationship, as France and co-workers reported in a similar IMFC reaction.<sup>2b</sup> On exposure of 4a to PPA for a long time, a slow decomposition to intractable polar compounds was observed. The decomposition was accelerated at elevated temperature (120 °C) in PPA presumably by the cleavage of the amide bond of the isatin moiety. The 6,5,6-tricyclic ring system of 4a was somewhat strained,<sup>2a,c</sup> thus an amide bond cleavage of the isatin moiety could proceed under the acidic conditions.<sup>9</sup> The reaction of 3a in the presence of H<sub>2</sub>SO<sub>4</sub> (5.0 equiv) in 1,2dichloroethane (reflux, 2 h) was ineffective. The formation of 4a was observed on TLC; however, both 3a and 4a were decomposed rapidly to intractable polar compounds. The use of CH<sub>3</sub>SO<sub>3</sub>H and AlCl<sub>3</sub> were also ineffective.

Thus, the IMFC reactions of 3b-f were carried out in PPA (90 °C), and the results are summarized in Table 1. The reactions of 3b (entry 2), 3e (entry 5), and 3f (entry 6) showed



Scheme 2. Preparation of starting materials.

		Time	
Entry	Substrate	(h)	Products (%)
1	3a	4	$\begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $
2	3b	4	Me Ne Ne Ne Ne Ne Ne Ne N
3 <sup>b</sup>	3с	9	$Cl \rightarrow O \qquad Cl \rightarrow O \qquad O$
4 <sup><i>c</i></sup>	3d	2	$MeO \xrightarrow{O} MeO \xrightarrow{O} O \xrightarrow{O} O$ $Ph \xrightarrow{E} O \xrightarrow{O} O \xrightarrow{V} O \xrightarrow{V} O$ $Ph \xrightarrow{E} O \xrightarrow{V} $
5	3e	4	CI 4e (63) 5e (12) CI
6	3f	4	$Me \qquad 4f (70) \qquad 5f (-)^d \qquad Me$

 Table 1. Synthesis of pyrrolo[3,2,1-ij]quinolines 4a-4f.

<sup>*a*</sup> Substrate **3** (0.5 mmol) was used in PPA (1.0 g) at 90 °C for given time. <sup>*b*</sup> Compound **3c** (9%) was recovered.

<sup>c</sup> Compound **3d** (12%) was recovered.


<sup>d</sup>Compounds **5c**, **5d** and **5f** were not isolated in appreciable amounts.

similar reactivity as that of 3a, and the corresponding products 4b, 4e, and 4f were obtained in good yields (62–70%). However, the reaction of 5-chloroisatin derivative 3c (entry 3) showed somewhat sluggish reactivity, and 4c was obtained in low yield (38%) for 9 h. When we increased the reaction time, the yield of 4c decreased because of decomposition to polar side products. The situation was similar for 5-methoxyisatin derivative **3d** (entry 4), and compound **4d** was obtained in low yield (42%). The Friedel–Crafts acylation products **5b** (entry 2) and **5e** (entry 5) were isolated in low yields; however, **5c**, **5d**, and **5f** could not be isolated in appreciable amount.


As a next entry, we prepared 3g-j by the alkylation of isatins 2a-d with cinnamyl bromide, as shown in Scheme 3. The reactions of 3g-j under the standard condition (PPA, 90 °C) afforded 4g-j in good to moderate yields (41–81%). As we observed for the synthesis of 4c and 4d (entries 3 and 4 in Table 1), the yields of 4i and 4j were relatively low compared to the other products 4g and 4h.

In contrast to *N*-cinnamyl derivatives 3g-j, unfortunately, the reactions of *N*-(but-2-enyl)isatin (**3k**) and *N*-(3-methylbut-2-enyl)isatin (**3l**) failed to afford the corresponding IMFC reaction products, as shown in Scheme 4. Under the typical reaction condition, hydration products **6a** and **6b** were formed in good yields (87 and 86%, respectively). The reactions of **3k** and **3l** in PPA at elevated temperature (120 °C, 4 h) showed complete decomposition to intractable polar compounds.


5-Benzylidenepyrrolo[3,2,1-ij]quinoline-1,2,6-trione derivative **5a** could be synthesized as a major product by using the carboxylic acid derivative of **3a**, as shown in Scheme 5. Base hydrolysis of **3a** afforded **7** in good yield (94%), and



Scheme 3. Synthesis of pyrrolo[3,2,1-ij]quinolines 4g-j.



Scheme 4. Trials of IMFC reaction of 3k and 3l.



Scheme 5. Selective synthesis of 5a.

the IMFC reaction of **7** gave **5a** as the sole product (74%). The corresponding Friedel–Crafts alkylation product was not formed in the reaction, and the result showed that Friedel–Crafts acylation is more effective than the alkylation with the carboxylic acid derivative **7**.

In summary, the first successful IMFC cyclization of *N*cinnamylisatin derivatives in PPA provided pyrrolo[3,2,1-*ij*] quinoline-1,2-diones in good to moderate yields. The electron-deficient benzene ring of isatin could be used effectively in the IMFC reaction in PPA, although some restrictions are still present.

## Experimental

The starting materials **3a–l** were prepared according to the reported method, <sup>5a,5b,7</sup> and the spectroscopic data of the unknown compounds are reported in Supporting Information. **Typical Procedure for the Synthesis of 4a and 5a.** A mixture of **3a** (161 mg, 0.5 mmol) and PPA (1.0 g) was heated to 90 °C for 4 h. After the usual aqueous extractive work-up and column chromatographic purification process (hexanes/CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O, 10:10:1), compounds **4a** (110 mg, 68%) and **5a** (22 mg, 15%) were isolated as orange solids. Other compounds were synthesized similarly, and the selected spectroscopic data of **4a–d**, **4g**, **5a**, and **5b** are as follows:

**Compound 4a**: 68%; orange solid, m.p. 186–188 °C; IR (KBr) 1740, 1626, 1603, 1474 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)  $\delta$  3.14 (ddd, J=7.2, 6.6 and 4.2 Hz, 1H), 3.61 (s, 3H), 3.89 (dd, J=13.2 and 4.2 Hz, 1H), 4.03 (dd, J=13.2 and 7.2 Hz, 1H), 4.52 (d, J=6.6 Hz, 1H), 7.02 (t, J=7.2 Hz, 1H), 7.12–7.16 (m, 3H), 7.31 (t, J=7.2 Hz, 1H), 7.34–7.39 (m, 2H), 7.48 (d, J=7.2 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz)  $\delta$  38.05, 43.19, 44.99, 52.51, 115.60, 122.43, 123.80, 123.93, 127.78, 128.45, 129.02, 137.80, 140.07, 146.58, 156.69, 171.42, 183.18; ESIMS *m/z* 322 [M<sup>+</sup>+H]. Anal. Calcd. for C<sub>19</sub>H<sub>15</sub>NO<sub>4</sub>: C, 71.02; H, 4.71; N, 4.36. Found: C, 70.91; H, 4.93; N, 4.18.

**Compound 4b**: 62%; orange solid, m.p. 182–184 °C; IR (KBr) 1740, 1624, 1489, 1349 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  2.24 (s, 3H), 3.10 (ddd, *J* = 6.6, 6.3 and 4.2 Hz, 1H), 3.60 (s, 3H), 3.80 (dd, *J* = 13.5 and 4.2 Hz, 1H), 4.04 (dd, *J* = 13.5 and 6.6 Hz, 1H), 4.49 (d, *J* = 6.3 Hz, 1H), 6.96 (s, 1H), 7.09–7.16 (m, 2H), 7.26–7.40 (m, 4H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  20.94, 37.78, 43.01, 45.16, 52.51, 115.63, 122.01, 124.36, 127.72, 128.43, 129.00, 133.74, 138.15, 140.33, 144.47, 156.79, 171.50, 183.44; ESIMS *m*/*z* 336 [M<sup>+</sup> + H]. Anal. Calcd. for C<sub>20</sub>H<sub>17</sub>NO<sub>4</sub>: C, 71.63; H, 5.11; N, 4.18. Found: C, 71.81; H, 5.30; N, 4.11.

**Compound 4c**: 38%; orange solid, m.p.  $214-216 \,^{\circ}$ C; IR (KBr) 1744, 1621, 1602, 1476 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  3.15 (ddd, J = 6.9, 6.6 and 4.2 Hz, 1H), 3.64 (s, 3H), 3.86 (dd, J = 13.5 and 4.2 Hz, 1H), 4.07 (dd, J = 13.5 and 6.9 Hz, 1H), 4.52 (d, J = 6.6 Hz, 1H), 7.10–7.17 (m, 3H), 7.31–7.44 (m, 3H), 7.47 (d, J = 1.8 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  37.94, 42.97, 44.79, 52.65, 116.36, 123.92, 124.11, 128.07, 128.35, 129.21, 129.72, 137.07,

139.44, 144.97, 156.13, 171.14, 182.07; ESIMS *m*/*z* 356 [M<sup>+</sup> + H], 358 [M<sup>+</sup>+H + 2].

**Compound 4d**: 42%; red solid, m.p. 166–168 °C; IR (KBr) 1739, 1630, 1616, 1490 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  3.12 (ddd, *J* = 6.9, 6.6 and 4.2 Hz, 1H), 3.60 (s, 3H), 3.71 (s, 3H), 3.83 (dd, *J* = 13.2 and 4.2 Hz, 1H), 4.01 (dd, *J* = 13.2 and 6.9 Hz, 1H), 4.48 (d, *J* = 6.6 Hz, 1H), 6.71 (d, *J* = 2.4 Hz, 1H), 7.02 (d, *J* = 2.4 Hz, 1H), 7.10–7.16 (m, 2H), 7.26–7.39 (m, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  37.91, 43.16, 45.25, 52.52, 55.92, 108.39, 115.89, 123.63, 124.20, 127.81, 128.44, 129.03, 139.96, 140.72, 156.66, 156.77, 171.42, 183.44; ESIMS *m/z* 352 [M<sup>+</sup>+H].

**Compound 4g**: 77%; orange solid, m.p. 137–139 °C; IR (KBr) 1737, 1601, 1473, 1353 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  2.09–2.24 (m, 1H), 2.26–2.39 (m, 1H), 3.68–3.86 (m, 2H), 4.14 (dd, *J* = 7.5 and 4.5 Hz, 1H), 6.97 (t, *J* = 7.5 Hz, 1H), 7.08–7.18 (m, 3H), 7.26–7.41 (m, 3H), 7.44 (d, *J* = 7.5 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  29.27, 36.72, 40.60, 115.75, 123.40, 123.55, 124.48, 127.33, 128.20, 128.92, 137.55, 141.92, 147.56, 156.85, 183.87; ESIMS *m*/*z* 264 [M<sup>+</sup> + H]. Anal. Calcd. for C<sub>17</sub>H<sub>13</sub>NO<sub>2</sub>: C, 77.55; H, 4.98; N, 5.32. Found: C, 77.51; H, 5.13; N, 5.19.

**Compound 5a**: 74%; orange solid, m.p. 198–200 °C; IR (KBr) 1744, 1663, 1619, 1443 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)  $\delta$  5.13 (d, *J* = 2.4 Hz, 2H), 7.24 (dd, *J* = 8.4 and 7.2 Hz, 1H), 7.42 (d, *J* = 7.2 Hz, 2H), 7.46–7.53 (m, 3H), 7.78 (dd, *J* = 7.2 and 1.2 Hz, 1H), 8.00 (t, *J* = 2.4 Hz, 1H), 8.17 (dd, *J* = 8.4 and 1.2 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz)  $\delta$  41.91, 116.39, 117.31, 124.07, 126.03, 129.02, 130.27, 130.52, 130.75, 133.75, 135.35, 140.77, 152.02, 156.82, 179.99, 181.16; ESIMS *m*/*z* 290 [M<sup>+</sup> + H]. Anal. Calcd. for C<sub>18</sub>H<sub>11</sub>NO<sub>3</sub>: C, 74.73; H, 3.83; N, 4.84. Found: C, 74.95; H, 4.01; N, 4.81.

**Compound 5b**: 14%; orange solid, m.p. 196–198 °C; IR (KBr) 1737, 1672, 1623, 1490 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  2.40 (s, 3H), 5.09 (d, J = 2.7 Hz, 2H), 7.37–7.53 (m, 5H), 7.58 (s, 1H), 7.94 (s, 1H), 7.97 (t, J = 2.7 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  20.92, 41.88, 116.48, 117.07, 126.32, 128.99, 130.20, 130.50, 131.54, 133.81, 134.26, 135.03, 140.53, 150.09, 156.91, 180.10, 181.39; ESIMS *m/z* 304 [M<sup>+</sup>+H].

Acknowledgments. This research was supported by THE Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2014R1A1A2053606). Spectroscopic data were obtained from the Korea Basic Science Institute, Gwangju branch.

**Supporting Information.** Additional supporting information is available in the online version of this article.

## References

 For the synthesis and biological activity of pyrrolo[3,2,1-*ij*]quinolines and related compounds, see:(a) M. Layek, M. A. Reddy, A. V. D. Rao, M. Alvala, M. K. Arunasree, A. Islam, K. Mukkanti, J. Iqbal, M. Pal, Org. Biomol. Chem. 2011, 9, 1004; (b) L. L. R. Rix, B. M. Kuenzi, Y. Luo, E. Remily-Wood, F. Kinose, G. Wright, J. Li, J. M. Koomen, E. B. Haura, H. R. Lawrence, U. Rix, ACS Chem. Biol. 2014, 9, 353; (c) H. S. Kim, M. G. Banwell, A. C. Willis, J. Org. Chem. 2013, 78, 5103; (d) D. Paris, M. Cottin, P. Demonchaux, G. Augert, P. Dupassieux, P. Lenoir, M. J. Peck, D. Jasserand, J. Med. Chem. 1995, 38, 669; (e) M. Isaac, A. Slassi, A. O'Brien, L. Edwards, N. MacLean, D. Bueschkens, D. K. H. Lee, K. McCallum, I. D. Lannoy, L. Demchyshyn, R. Kamboj, Bioorg. Med. Chem. Lett. 2000, 10, 919; (f) R. L. Dorow, P. M. Herrinton, R. A. Hohler, M. T. Maloney, M. A. Mauragis, W. E. McGhee, J. A. Moeslein, J. W. Strohbach, M. F. Veley, Org. Process Res. Dev. 2006, 10, 493; (g) R. S. Al-awar, J. E. Ray, K. A. Hecker, J. Huang, P. P. Waid, C. Shih, H. B. Brooks, C. D. Spencer, S. A. Watkins, B. R. Patel, N. B. Stamm, C. A. Ogg, R. M. Schultz, E. L. Considine, M. M. Faul, K. A. Sullivan, S. P. Kolis, J. L. Grutsch, S. Joseph, Bioorg. Med. Chem. Lett. 2004, 14, 3217.

- For the synthetic approaches of pyrrolo[3,2,1-*ij*]quinolines, see:

   (a) L. Matesic, J. M. Locke, K. L. Vine, M. Ranson, J. B. Bremner, D. Skropeta, *Tetrahedron* 2012, *68*, 6810; and further references cited therein;
   (b) D. V. Patil, M. A. Cavitt, P. Grzybowski, S. France, *Chem. Commun.* 2012, *48*, 10337;
   (c) D. S. Black, P. A. Keller, N. Kumar, *Tetrahedron* 1992, *48*, 7601;
   (d) D. S. Black, N. Kumar, P. S. R. Mitchell, *J. Org. Chem.* 2002, *67*, 2464;
   (e) X.-F. Yang, X.-H. Hu, T.-P. Loh, *Org. Lett.* 2015, *17*, 1481.
- For the construction of pyrrolo[3,2,1-*ij*]quinoline-1,2-diones by using oxalyl chloride (Stolle isatin synthesis), ethyl glyoxalate, or carbon monoxide, see:(a) M. Shamsi, M. M. Baradarani, A. Afghan, J. A. Joule, *ARKIVOC* 2011, *ix*, 252; (b) S. M. Medvedeva, M. Y. Krysin, F. I. Zubkov, E. V. Nikitina, K. S. Shikhaliev, *Chem. Heterocycl. Compd.* 2014, 50, 1280; (c) W. Li, Z. Duan, X. Zhang, H. Zhang, M. Wang, R. Jiang, H. Zeng, C. Liu, A. Lei, *Angew. Chem. Int. Ed.* 2015, 54, 1893; (d) T. Liu, H. Yang, Y. Jiang, H. Fu, *Adv. Synth. Catal.* 2013, 355, 1169.
- For our recent reports on IMFC reactions, see:(a) H. R. Moon,
   J. Yu, K. H. Kim, J. N. Kim, *Bull. Korean Chem. Soc.* 2015, 36, 1189; (b) K. H. Kim, H. S. Lee, J. N. Kim, *Tetrahedron Lett.* 2009, 50, 1249; (c) B. R. Park, S. H. Kim, Y. M. Kim, J. N. Kim,

*Tetrahedron Lett.* **2011**, *52*, 1700; (d) S. Gowrisankar, K. Y. Lee, C. G. Lee, J. N. Kim, *Tetrahedron Lett.* **2004**, *45*, 6141.

- For our recent chemical transformations of isatin derivatives including palladium-catalyzed C<sub>7</sub>-N annulations, see:
   (a) H. S. Lee, K. H. Kim, Y. M. Kim, J. N. Kim, Bull. Korean Chem. Soc. 2010, 31, 1761; (b) H. S. Lee, S. H. Kim, S. Gowrisankar, J. N. Kim, Tetrahedron 2008, 64, 7183; (c) S. C. Kim, K. Y. Lee, S. Gowrisankar, J. N. Kim, Bull. Korean Chem. Soc. 2006, 27, 1133; (d) S. C. Kim, S. Gowrisankar, J. N. Kim, Tetrahedron Lett. 2006, 47, 3463.
- For the general review on Morita-Baylis-Hillman reaction, see:

   (a) D. Basavaiah, A. J. Rao, T. Satyanarayana, *Chem. Rev.* 2003, 103, 811;
   (b) D. Basavaiah, B. S. Reddy, S. S. Badsara, *Chem. Rev.* 2008, 64, 4511;
   (d) V. Declerck, J. Martinez, F. Lamaty, *Chem. Rev.* 2009, 109, 1;
   (e) E. Ciganek, In *Organic Reactions*, Vol. 51, L. A. Paquette Ed., John Wiley & Sons, New York, 1997, p. 201;
   (f) J. N. Kim, K. Y. Lee, *Curr. Org. Chem.* 2002, 6, 627;
   (g) K. Y. Lee, S. Gowrisankar, J. N. Kim, *Bull. Korean Chem. Soc.* 2005, 26, 1481;
   (h) S. Gowrisankar, H. S. Lee, S. H. Kim, K. Y. Lee, J. N. Kim, *Tetrahedron* 2009, 65, 8769;
   (i) M. Shi, F.-J. Wang, M.-X. Zhao, Y. Wei, *The Chemistry of the Morita-Baylis-Hillman Reaction*, RSC Publishing, Cambridge, UK, 2011.
- (a) H. S. Lee, K. H. Kim, S. H. Kim, J. N. Kim, *Adv. Synth. Catal.* **2012**, *354*, 2419; (b) S. B. Kumar, M. Ravinder, G. Kishore,
   V. J. Rao, P. Yogeeswari, D. Sriram, *Med. Chem. Res.* 2014, 23, 1934.
- For our recent contributions on Friedel-Crafts reactions in PPA, see:(a) C. G. Lee, K. Y. Lee, S. Gowrisankar, J. N. Kim, *Tetrahedron Lett.* 2004, 45, 7409; (b) C. G. Lee, K. Y. Lee, S. Lee, J. N. Kim, *Tetrahedron* 2005, 61, 1493; (c) K. H. Kim, S. H. Kim, K. Y. Lee, J. N. Kim, *Bull. Korean Chem. Soc.* 2011, 32, 1387; (d) S. C. Kim, S. Gowrisankar, J. N. Kim, *Bull. Korean Chem. Soc.* 2005, 26, 1001.
- For ring-opening of isatin derivatives, see:(a) T. Le, W. C. Cheah, K. Wood, D. S. Black, M. D. Willcox, N. Kumar, *Tetrahedron Lett.* 2011, 52, 3645; (b) H. Li, B. Cheng, N. Boonnak, A. Padwa, *Tetrahedron* 2011, 67, 9829; (c) Y. Zhang, L. Wang, Y. Zhu, J.-H. Xu, *Eur. J. Org. Chem.* 2004, 527; (d) Y. M. Chung, J. M. Kim, J. N. Kim, *Bull. Korean Chem. Soc.* 2003, 24, 141; (e) Y. M. Chung, J. H. Gong, J. N. Kim, *Bull. Korean Chem. Soc.* 2002, 23, 1363.